 |
인쇄하기
취소
|
Merck's new oral antidiabetic agent joins domestic type 2 diabetes market
A new diabetes medication has joined the arsenal of drugs available to treat type 2 diabetes.
The Korea Food and Drug Administration (KFDA) has recently approved sitagliptin phosphate (Januvia), an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors.
Taken as a once-a-day tablet, Januvia enhances the body's ability to lower elevated blood sugar.
Januvia blocks a...
The Korea Food and Drug Administration (KFDA) has recently approved sitagliptin phosphate (Januvia), an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors.
Taken as a once-a-day tablet, Januvia enhances the body's ability to lower elevated blood sugar.
Januvia blocks a...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.